Nanobiotix S.A. (NBTX) Form 6-K — Jun 2, 2026
Nanobiotix reported a €86.1 million follow-on offering in May 2026, which, combined with its existing cash position, extends its operational runway into 2029. This capital infusion secures funding for the development of its nanotherapeutic platforms through the critical late-stage clinical phases. The company presented positive Part 1 data from the J&J-sponsored Phase 2 CONVERGE study for JNJ-1900 (NBTXR3) in Stage 3 NSCLC, showing an 85.7% overall response rate and 57.1% complete response rate in a small cohort. These results demonstrate deep tumor regression and safety, supporting the potential for long-term durability in this difficult-to-treat population.
Key figures
- Cash Position
- 42.1 million EUR
- Gross Proceeds
- 86.1 million EUR
- Cash runway end
- 2029
- Crr converge study
- 57.1%
- Orr converge study
- 85.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.